Tests tirzepatide effects on muscle in people with obesity
Tests tirzepatide against placebo on muscle in premenopausal women with obesity.
Plain-language title generated from the registry record
Registry title: Tirzepatide and Muscle Outcomes in Obesity
Key facts
- Where
- Ljubljana, SloveniaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT07373834, who can take part
Where in Slovenia
- Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre LjubljanaLjubljana, SloveniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Medical Centre Ljubljana
- Trial code
- NCT07373834
- Record updated
- 28 January 2026
- Original description
This study is evaluating whether a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, can affect the function, structure and metabolism of skeletal muscles in adults with obesity. Participants, premenopausal females with obesity, will receive either tirzepatide or placebo over 24 weeks. Researchers will assess body weight, body composition, muscle strength and functional performance, neuromuscular function and will perform muscle biopsies before and after treatment to study molecular and histological changes following treatment. The goal of this study is to investigate the effects of tirzepatide on skeletal muscle function, quantity, quality and metabolism in adults with obesity as well as clarify the molecular and structural adaptations in skeletal muscle during tirzepatide-induced weight loss, addressing an important gap in understanding the impact of incretin-based therapies on muscle health.Read full original descriptionShow less
Effects of Tirzepatide on Skeletal Muscle in Obesity
This study is evaluating whether a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, can affect the function, structure and metabolism of skeletal muscles in adults with obesity. Participants, premenopausal females with obesity, will receive either tirzepatide or placebo over 24 weeks. Researchers will assess body weight, body composition, muscle strength and functional performance, neuromuscular function and will perform muscle biopsies before and after treatment to study molecular and histological changes following treatment. The goal of this study is to investigate the effects of tirzepatide on skeletal muscle function, quantity, quality and metabolism in adults with obesity as well as clarify the molecular and structural adaptations in skeletal muscle during tirzepatide-induced weight loss, addressing an important gap in understanding the impact of incretin-based therapies on muscle health.
Inclusion: Female sex; Age between 18 and 50 years; BMI between 30 kg/m² and 40 kg/m²; Stable body weight within the three months preceding study enrolment (defined as ≤ 5% change); No prior pharmacological or surgical interventions for obesity treatment; Commitment to use barrier contraception and absence of plans for pregnancy within 8 months following enrolment.
Exclusion: Current treatment with metformin or systemic corticosteroids; Diabetes; Personal history of malignancy; Personal history of pancreatitis; Personal history of major depressive episodes; Personal history of myopathy; Personal or family history of medullary thyroid carcinoma; Sarcopenic obesity; Pregnancy or lactation; Postmenopausal status; Immobility.